Disease Registry on Patients with Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/47603
• EU PAS number:
  EUPAS47602
• Study ID:
  47603
• Official title and acronym:
  Disease Registry on Patients with Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
• DARWIN EU® study:
  No
• Study countries:
  Germany

  United States
• Study description:
  The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants, demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy. This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Merck Healthcare KGaA

Germany

Study timelines

Date when funding contract was signed

Planned: 30/06/2022

Study start date

Planned: 30/06/2022

Actual: 04/03/2022

Date of final study report

Planned: 31/03/2027

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Merck KGaA

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable